SCENDIA PURCHASE AGREEMENT (Tables)

3 Months Ended

Mar. 31, 2023

Restructuring Cost and Reserve [Line Items]

SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED

Balance December 31, 2022	$	7,166,691
Additions		-
Changes in fair value of earnout liabilities		(452,687	)
Settlements		-
Balance March 31, 2023	$	6,714,004

Scendia Biologics LLC [Member]

Restructuring Cost and Reserve [Line Items]

SCHEDULE OF PURCHASE CONSIDERATIONS

The total purchase consideration, subject to typical post-closing adjustments, as determined by the Company was as follows:

Consideration	Equity Shares		Dollar Value
Fair value of Sanara common shares issued		291,686	$	6,032,066
Cash consideration				1,562,668
Fair value of contingent earnout consideration				3,000,000
Total purchase consideration			$	10,594,734

SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED

Description	Amount
Cash	$	201,406
Net working capital (excluding cash)		1,294,499
Fixed assets, net		42,300
Noncontrolling interest in Sanara Biologics, LLC		2,638
Customer relationships		7,155,000
Deferred tax liabilities		(1,702,890	)
Goodwill		3,601,781
Net assets acquired	$	10,594,734